比阿培南联合莫西沙星对老年重症肺炎患者炎性指标及不良反应的影响

doi:10.3969/j.issn.1006-6233.2020.05.005

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1222 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective:To investigate the clinical effect of biapenem combined with moxifloxacin in the treatment of elderly severe pneumonia (SP). Methods: Eighty-one elderly patients with SP in our hospital from June 2016 to July 2019 were selected and divided into three groups according to different treatment, 27 cases in each. All three groups were treated with routine treatment. The control group one was treated with biapenem, the control group two was treated with moxifloxacin, and the observation group was treated with biapenem combined with moxifloxacin. Comparison was made in fficacy, clinical symptoms and signs improvement time, detection rate of pathogenic bacteria before and after treatment, inflammatory factors [serum calcitonin (PCT), white blood cell count (WBC), high-sensitivity C-reactive protein (hs-CRP)], T-lymph Cell subsets (CD3, CD4, CD8) levels in three groups.The incidence of adverse reactions in the three groups was counted. Results: The total effective rate of observation group was 92.59% (25/27) higher than that of control group one and control group two. The detection rate of gram-negative bacteria after treatment was 7.41% (2/27) lower than that of control group one and control group two (P<0.05); mechanical ventilation time, antipyretic time, sputum trait change time, leukocyte decline time, and significant pulmonary inflammation absorption time in the observation group were shorter than those in control group one and control group two (P<0.05); After treatment, the levels of PCT, WBC and hs CRP in the observation group were lower than those in the control group one and two, and the levels of CD3, CD4 and CD8 were higher than those in the control group one and two (P<0.05).Conclusion: Biapenem combined with moxifloxacin has significant curative effect on elderly SP. It can inhibit the inflammatory response and improve immune function, with less adverse reactions and high safety.

Key words： Biapenem Moxifloxacin Severe pneumonia T lymphocyte subsets Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.05.005 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I5/721

[1] Phua J,Dean NC,Guo Q,et al.Severe community-acquired pneumonia: Timely management measures in the first 24 hours[J].Crit Care,2016,20(1):237.
[2] 龙思琪,马莉,陈敏,等.婴幼儿重症和非重症肺炎淋巴细胞亚群的差异分析[J].中国免疫学杂志,2016,32(3):401~404.
[3] 中国医师协会急诊医师分会.中国急诊重症肺炎临床实践专家共识[J].中国急救医学,2016,36(2):97~107.
[4] 巫太平,刘玲.血清S-ChE LPO及血常规联合检测对老年重症肺炎预后的评估[J].河北医学,2019,25(9):1459~1462.
[5] 孙兵,唐晓,李绪言,等.2017-2018年冬春季重症流感病毒性肺炎所致急性呼吸窘迫综合征的临床特点及预后危险因素分析[J].中华结核和呼吸杂志,2019,42(1):9~14.
[6] 薛世民,蒋伟,贾娟,等.莫西沙星治疗老年支原体肺炎患者的临床疗效分析[J].现代生物医学进展,2016,16(18):3551~3554.
[7] 何清,刘韬滔,冯喆.亚胺培南与莫西沙星治疗重症肺炎的临床疗效对比研究[J].国际呼吸杂志,2018,38(6):414~418.
[8] 马丽苹,徐若华,詹秀玲,等.比阿培南联合左氧氟沙星治疗老年重症肺炎的临床效果观察[J].临床误诊误治,2017,30(12):83~86.
[9] Mizgerd JP.Pathogenesis of severe pneumonia: advances and knowledge gaps[J].Curr Opin Pulm Med,2017,23(3):193~197.
[10] 付小龙,段伟,苏崇余,等.IL-6协同M-CSF体外诱导CD14~+单核细胞向M2样巨噬细胞分化[J].免疫学杂志,2016,32(12):1013~1018.
[11] Feucht J,Kayser S,Gorodezki D,et al.T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts[J].Oncotarget,2016,7(47):76902~76919.
[12] 李瑞萍,宋伟.血浆sTREM-1、sFLT-1及APACHEⅡ评分对重症肺炎患者预后评估价值[J].国际呼吸杂志,2018,38(13):968~971.